Compare PBYI & ECBK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PBYI | ECBK |
|---|---|---|
| Founded | 2010 | 1919 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 263.4M | 153.5M |
| IPO Year | N/A | N/A |
| Metric | PBYI | ECBK |
|---|---|---|
| Price | $6.01 | $17.33 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $7.00 | N/A |
| AVG Volume (30 Days) | ★ 396.5K | 15.3K |
| Earning Date | 11-06-2025 | 02-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 59.87 | ★ 104.95 |
| EPS | 0.74 | ★ 0.80 |
| Revenue | ★ $211,995,000.00 | $29,860,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ $8.20 | $21.67 |
| Revenue Growth | N/A | ★ 20.84 |
| 52 Week Low | $2.58 | $12.56 |
| 52 Week High | $6.27 | $17.75 |
| Indicator | PBYI | ECBK |
|---|---|---|
| Relative Strength Index (RSI) | 64.02 | 56.68 |
| Support Level | $5.81 | $17.15 |
| Resistance Level | $6.27 | $17.42 |
| Average True Range (ATR) | 0.23 | 0.21 |
| MACD | 0.03 | -0.00 |
| Stochastic Oscillator | 69.46 | 87.13 |
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis resulting into apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.
ECB Bancorp Inc operates as a bank holding company of Everett Co-operative Bank. The firm through its subsidiary engages in business consisting of taking deposits from the general public and investing those deposits, together with funds generated from operations, in one- to four-family residential real estate loans, commercial real estate, and multifamily real estate loans, construction and land loans and home equity lines of credit.